|
Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma
|
August 23, 2023
|
PC3I Authors Emily Ko |
Gynecologic Oncology
|
|
Role of immunotherapy for lymph node positive vulvar melanoma: utilization and outcomes
|
September 4, 2023
|
PC3I Authors Emily Ko |
International Journal of Gynecological Cancer
|
|
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes
|
September 25, 2023
|
PC3I Authors Emily Ko |
Gynecologic Oncology
|
|
Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery
|
October 25, 2023
|
PC3I Authors Emily Ko |
International Journal of Gynecological Cancer
|
|
Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions
|
November 29, 2023
|
PC3I Authors Emily Ko |
Gynecologic Oncology
|
|
Impact of delayed interval cytoreductive surgery on the survival of patients with advanced stage high-grade epithelial ovarian carcinoma
|
December 13, 2023
|
PC3I Authors Emily Ko |
International Journal of Gynecological Cancer
|
|
Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy
|
January 25, 2024
|
PC3I Authors Emily Ko |
Current Treatment Options in Oncology
|
|
Federal Transportation Regulations Limit Access to Clinical Trials and Oncology Care
|
February 1, 2024
|
PC3I Authors Anna Jo Smith; Emily Ko |
JAMA Oncology
|
|
Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities?
|
February 6, 2024
|
PC3I Authors Anna Jo Smith; Emily Ko |
Gynecologic Oncology
|
|
Financial toxicity in gynecologic oncology: a multi-practice survey
|
February 12, 2024
|
PC3I Authors Anna Jo Smith; Meredith Doherty; Emily Ko |
International Journal of Gynecological Cancer
|
|
Prior authorization for FDA-approved PARP inhibitors in ovarian cancer
|
February 23, 2024
|
PC3I Authors Anna Jo Smith; Emily Ko |
Gynecologic Oncology Reports
|
